BioSig Technologies to Present at The MicroCap Conference on October 5th in New York City at the Essex House
NEW YORK, NY / ACCESSWIRE / September 26, 2017 / BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need within the $4+ billion electrophysiology (EP) marketplace, will be presenting at this year's MicroCap Conference on October 5th in New York City.
Mr. Kenneth L. Londoner, Chairman & CEO of BioSig Technologies, will be giving the presentation and meeting with investors. The presentation will focus on the Company's PURE EP™ System, a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. The presentation will also cover recent Company developments and current marketplace. To arrange a meeting with management, please email Lora Mikolaitis at email@example.com.
CONFERENCE OVERVIEW AND STRUCTURE
The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors.
The MicroCap Conference will take place in New York City at the Essex House on October 5th. Registration will begin on Thursday at 7:00 AM, and will last until the evening. These days will be jam-packed with company sessions, presentations, good food, and plenty of time to network with other investors over drinks at the reception. This event does not allow service providers - only portfolio managers, analysts, and private investors.
REGISTRATION FOR INVESTORS
To register, please go to our website (microcapconf.com/conferences/new-york-2-2017/), and click "Investor Registration."
For our most updated list of companies, please go to our website (microcapconf.com/conferences/new-york-2-2017/)
- The Special Equities Group
- Maxim Group
- M2 Compliance
- MZ Group
- Pryor Cashman
- Wexler Burkhart Hirschberg & Unger
- IRTH Communications
- PCG Advisory Group
- CORE IR
- Catalyst IR
News Compliments of ACCESSWIRE.
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary technology platform designed to improve the $4+ billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market.
The PURE EP System is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig's main goal is to deliver technology to improve upon catheter ablation treatments for prevalent and deadly arrhythmias. BioSig has partnered with Minnetronix on technology development.
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates.. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Name: Lora Mikolaitis
FOR MORE INFORMATION
SOURCE: BioSig Technologies, Inc.
Released September 26, 2017